{"name":"Actelion","slug":"actelion","ticker":"","exchange":"","domain":"","description":"Actelion Pharmaceuticals Ltd. is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel, Switzerland. The company is part of Johnson & Johnson Innovative Medicine business segment.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"oncology","drugs":[{"name":"ACT-128800","genericName":"ACT-128800","slug":"act-128800","indication":"Pulmonary arterial hypertension","status":"phase_2"},{"name":"ACT-293987","genericName":"ACT-293987","slug":"act-293987","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"EFI/ACT-385781A","genericName":"EFI/ACT-385781A","slug":"efi-act-385781a","indication":"Pulmonary arterial hypertension","status":"phase_3"},{"name":"FDC macitentan/tadalafil","genericName":"FDC macitentan/tadalafil","slug":"fdc-macitentan-tadalafil","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"Macitentan/Tadalafil FDC","genericName":"Macitentan/Tadalafil FDC","slug":"macitentan-tadalafil-fdc","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"SOC: Soluble guanylate cyclase stimulator","genericName":"SOC: Soluble guanylate cyclase stimulator","slug":"soc-soluble-guanylate-cyclase-stimulator","indication":"Pulmonary arterial hypertension","status":"phase_3"},{"name":"Tracleer®","genericName":"Tracleer®","slug":"tracleer","indication":"Pulmonary arterial hypertension (PAH), WHO Group 1","status":"marketed"},{"name":"i.v. selexipag","genericName":"i.v. selexipag","slug":"i-v-selexipag","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"iloprost (5 µg)","genericName":"iloprost (5 µg)","slug":"iloprost-5-g","indication":"Pulmonary arterial hypertension","status":"phase_3"},{"name":"macitentan (ACT-064992)","genericName":"macitentan (ACT-064992)","slug":"macitentan-act-064992","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"selexipag (Uptravi)","genericName":"selexipag (Uptravi)","slug":"selexipag-uptravi","indication":"Pulmonary arterial hypertension","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Flolan®","genericName":"Flolan®","slug":"flolan","indication":"Other","status":"marketed"},{"name":"JNJ-67896049","genericName":"JNJ-67896049","slug":"jnj-67896049","indication":"Other","status":"marketed"},{"name":"Ponesimod 80 mg","genericName":"Ponesimod 80 mg","slug":"ponesimod-80-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ACT-128800","genericName":"ACT-128800","slug":"act-128800","phase":"phase_2","mechanism":"ACT-128800 is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor.","indications":["Pulmonary arterial hypertension"],"catalyst":""},{"name":"ACT-293987","genericName":"ACT-293987","slug":"act-293987","phase":"phase_3","mechanism":"ACT-293987 is a selective soluble guanylate cyclase (sGC) stimulator that increases intracellular cGMP levels to promote vasodilation and reduce fibrosis.","indications":["Pulmonary arterial hypertension (PAH)","Chronic thromboembolic pulmonary hypertension (CTEPH)"],"catalyst":""},{"name":"EFI/ACT-385781A","genericName":"EFI/ACT-385781A","slug":"efi-act-385781a","phase":"phase_3","mechanism":"EFI/ACT-385781A is a selective endothelin receptor antagonist that blocks endothelin-1 signaling to reduce pulmonary vascular resistance and improve hemodynamics.","indications":["Pulmonary arterial hypertension"],"catalyst":""},{"name":"FDC macitentan/tadalafil","genericName":"FDC macitentan/tadalafil","slug":"fdc-macitentan-tadalafil","phase":"phase_3","mechanism":"This fixed-dose combination blocks endothelin-1 receptors (via macitentan) and phosphodiesterase-5 (via tadalafil) to reduce pulmonary vascular resistance and improve exercise capacity in pulmonary arterial hypertension.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"Flolan®","genericName":"Flolan®","slug":"flolan","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-67896049","genericName":"JNJ-67896049","slug":"jnj-67896049","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Macitentan/Tadalafil FDC","genericName":"Macitentan/Tadalafil FDC","slug":"macitentan-tadalafil-fdc","phase":"phase_3","mechanism":"This fixed-dose combination blocks endothelin-1 receptors (via macitentan) to reduce pulmonary vascular resistance while simultaneously inhibiting phosphodiesterase-5 (via tadalafil) to promote vasodilation in the pulmonary circulation.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"Ponesimod 80 mg","genericName":"Ponesimod 80 mg","slug":"ponesimod-80-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SOC: Soluble guanylate cyclase stimulator","genericName":"SOC: Soluble guanylate cyclase stimulator","slug":"soc-soluble-guanylate-cyclase-stimulator","phase":"phase_3","mechanism":"Soluble guanylate cyclase stimulators directly activate the enzyme soluble guanylate cyclase to increase intracellular cyclic GMP levels, promoting vasodilation and reducing pulmonary vascular resistance.","indications":["Pulmonary arterial hypertension","Chronic thromboembolic pulmonary hypertension"],"catalyst":""},{"name":"Tracleer®","genericName":"Tracleer®","slug":"tracleer","phase":"marketed","mechanism":"Tracleer blocks endothelin-1 receptors on vascular smooth muscle cells, preventing vasoconstriction and reducing pulmonary vascular resistance.","indications":["Pulmonary arterial hypertension (PAH), WHO Group 1","Pulmonary hypertension associated with connective tissue disease"],"catalyst":""},{"name":"i.v. selexipag","genericName":"i.v. selexipag","slug":"i-v-selexipag","phase":"phase_3","mechanism":"Selexipag is a prostacyclin receptor agonist that acts as a potent vasodilator.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"iloprost (5 µg)","genericName":"iloprost (5 µg)","slug":"iloprost-5-g","phase":"phase_3","mechanism":"Iloprost is a prostacyclin analogue that acts as a vasodilator and inhibits platelet aggregation.","indications":["Pulmonary arterial hypertension"],"catalyst":""},{"name":"macitentan (ACT-064992)","genericName":"macitentan (ACT-064992)","slug":"macitentan-act-064992","phase":"phase_3","mechanism":"Macitentan is a dual endothelin receptor antagonist that blocks both ETA and ETB receptors to reduce pulmonary vascular resistance and improve exercise capacity in pulmonary arterial hypertension.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"selexipag (Uptravi)","genericName":"selexipag (Uptravi)","slug":"selexipag-uptravi","phase":"phase_3","mechanism":"Selexipag is a prostacyclin receptor agonist that acts as a selective IP receptor agonist.","indications":["Pulmonary arterial hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxObnlrcTJHd1ZWRkF0T295aklFT3Z1Z1hyY0tfT3h0M2dkdVB0eWJVa2toVm5zTkJJN0ZlLTlVLW56N2NQZUd0eEhZQ3JYY0pBVnFFeWtnaEIzWVg5R25MX0dtYi1lMGM1d2xaZUc0cUIyaVltN09XNVN6Z1BjanJVcUpVelBSYURNV21abHNXQXktZTJvNlBGMm5qd1VNVkxTaHA4OUVWXzl2S0o1Wl96T0gwV3FCQWRxbWgxc1RJNjRCbmpiWkVF?oc=5","date":"2026-03-05","type":"pipeline","source":"Reuters","summary":"Johnson & Johnson units to pay $65 million to settle Tracleer antitrust class action - Reuters","headline":"Johnson & Johnson units to pay $65 million to settle Tracleer antitrust class action","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOVHM0cmNITFNyZENoZTRiUXhOTXFPZWE1TFg2ejNIMTZpVHR1WXBwcWtuSnBuYjBDOUVGSlNkcHNsY3ZvR2NXSDJOMEFXWWhjSG1DWDJoazlWN2JhUE83Nlo4VWpNYUhCSFd3THhhQ1k0dVRKSERIZmNhRFVzejE3SHp4YlhyYVRWZVhEb0R5VTlqcnhSX1ZCSmNrc0NoZVhQWFhZWHVfd2xPOF85dUYycFBFSEVYeFA50gG-AUFVX3lxTFAzaHBGRzlfVlBWOVJBX3NzY0NZbVJPLUlsc25XSzJJZlNVd1RSUjN1dDZHOFItcF8tTVl2Um9qVWUzbVRoR1lPWHhyTUlLTk5Ib2lmeE0zT0V3OWZGQ3N1d3VVR1VBNlZTTzEtTEJMcVBSNVRiS1BjZFFobldaUUFod1R1MEhZVkVHY0llUWdBaHpxX1U1YlktWEcxVl9QcGkwVXJsWW1fWmhwQ2tPQ0pvRjJ2Q1B1b09mbGZXLUE?oc=5","date":"2025-08-20","type":"patent","source":"Express Pharma","summary":"NATCO Pharma launches generic Bosentan tablets for oral suspension in the United States - Express Pharma","headline":"NATCO Pharma launches generic Bosentan tablets for oral suspension in the United States","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPUWhpMlc4WW1NR2RGOE5EQ2JHa3hBUTBPMXQyX2t2YVdLWU5WMllPTEtsV0k0cUpYVVVIQ1JzWVpWenRpcklwT09CRDlVNjU2UnpzOWZGZU9SeWhrZjROOW1uazlMaXFBNGRONFFjM04wTEd2d3lyNHRkVFdzdjVsTnRlS0t5WjlBanpsNHNsaHJIMnJFNUh1bkhLbFptbjE2Ny1WV3VMTVpTZ9IBrwFBVV95cUxQVHFKUmhrazZhckV3cTlxQ3RfRTBHeHdRRVI5Nk1wYXRQeGxDQkFtcWZCZ1EzMGFJNDY3NElIV1pvOWZmdlZtUEdQM3F0UUxKT3lxSTF3NjdZSHdQUjRNeVZpeV9Pdkczd3lHN3V4M3ZPSFVGSjhSMlRXNEJDYmJWbDZHUW16Y3Ywa1M0R3lONnQ5dlk2SHJURDlyUkZBX1hFRmp3TFplUndRQ3pNeERn?oc=5","date":"2025-08-19","type":"regulatory","source":"Express Pharma","summary":"Alembic Pharmaceuticals receives USFDA approval for Macitentan Tablets, 10 mg - Express Pharma","headline":"Alembic Pharmaceuticals receives USFDA approval for Macitentan Tablets, 10 mg","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxObmdTaWlGQk9DSnFpMGFWMVMtc09ySDQ3RFY2bElrMnVjQUR2LU5Qd0ZtY3FQVF9TTVQ1cE1Qb2VtYTZnUWE0TGJISVlLRkdiVUh2V3hJTjhQZWFNei1NMVFPWHgzMjRQMTdLbUxVQVBCcDhPdlgzdDFpMFJYNnVJMmhR?oc=5","date":"2023-12-08","type":"deal","source":"Pharmaceutical Technology","summary":"Vanda acquires rights to Actelion’s multiple sclerosis drug - Pharmaceutical Technology","headline":"Vanda acquires rights to Actelion’s multiple sclerosis drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPY0VaeWRLbkhMOXdzbDdSS3N4M2NZSnZkcG5VR3UwSFlZeHl3dkFCUERfOXc3d2M2anBmVTlsd2dqV3BHbFRpMko5d2E4NnJFcHFiMVIwdWgtX2ctQmQ1Z3lkbDU0T3MtckxVdnlua21Ubzc0aEh1azVuYVh1ZFo1eHRyandGc1I2TzlaVGZibE54d1lDbWdDSlkza04?oc=5","date":"2023-12-08","type":"deal","source":"BioSpace","summary":"Vanda Buys US, Canadian Rights to J&J’s MS Drug Ponvory in $100M Deal - BioSpace","headline":"Vanda Buys US, Canadian Rights to J&J’s MS Drug Ponvory in $100M Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOTGR4QXZkZmtyeWE1QnVuWmgxUHlJQjN4X016UFNLT1pFOEZ4U3FrTkRiTUQ3dTBPYk9nOXQ5TG43MGFjVEZVVmpBNmhqVmt3THhtZGxtVlExS0V3cUh6ZWE2NXRfQ0c2R2otX1d0WjlpS0YzWVl5RFJDWFh4V1FsMFNSTkhrNFpHZkd2UDB0SmdDV0YwaHc?oc=5","date":"2018-03-21","type":"pipeline","source":"Contract Pharma","summary":"Helsinn Group, Actelion Pharma Enter Agreement - Contract Pharma","headline":"Helsinn Group, Actelion Pharma Enter Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPN3cwZC1iYjNjVmJvOFQtVTg5VzZEc0RWNDY2YVNQRFhGTVVBV1AybzdSbHk2dUNsZmUxajg3TlJNcWpxUVRfMHZKY2E5Z1MzdlhJT2U5NTVucms1bWFfY3Z3WnR0Wkt4SjJBaHVnN1hxLV91OEc0bDlJWnpXczAwSzllTVJsZGZMd0E2TkM1TW9QZWdBYUZMSQ?oc=5","date":"2017-12-04","type":"pipeline","source":"BioPharma Dive","summary":"J&J jumps in on Actelion spinout’s hypertension drug - BioPharma Dive","headline":"J&J jumps in on Actelion spinout’s hypertension drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZ2ZWcEs4aEIyaGxqUVM4VTFRVFVJMko2SGl0eGloSi1lNmpsVkViOUlhek9ta0xaYWI4a2RuUXEwd1plcGt2YlJUaEYybkNnUmNzcDg2TS1RX0xmcGFKT0g5UlpYaERyZUpmZzYwNUxkMWJ6M0wzYUpkYTBueEdSeDBvLUlJR2xXaFVaeW9nYUlzS09yQVkzR2IxMXd5dDZwQVdQQUs5eWx6Zw?oc=5","date":"2017-06-09","type":"regulatory","source":"Drug Delivery Business","summary":"Johnson & Johnson wins last regulatory nod needed for Actelion acquisition - Drug Delivery Business","headline":"Johnson & Johnson wins last regulatory nod needed for Actelion acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPWGFwUFVQT1N4REx1dE5lMmJheVBJeGoxVHRyXzY2TmUzcFdJZzJfMU1penBmU0NkUTR1TEN5TTJaUlNsc1AxVkd0RFdIOGRwZVNmVlllV0gxcGxaaUU2V0RnS1o4aFNleGJuLWg4ZF8yWTZUdUt2bnpXcDg5U29HOTBmUlpDUVFTUWQw?oc=5","date":"2017-01-26","type":"deal","source":"BioPharma Dive","summary":"J&J seals $30B deal for Actelion - BioPharma Dive","headline":"J&J seals $30B deal for Actelion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOUGFuVlU4dmRUMVRORm5icWNHRDUyODhITlViN2ZITVlKVG1XTHJtaFByc3RkY3RnTlZSMGM1MHlVTDJZVXUtYnhYeWh6NmdrTzl2alpLTG56OTRlRldaN3NucFV5STVDa1RDWUxIdm1tTkxLeC1zQVdnbmZsaHZuZEFTUTlJdkV5akhWWFpWVWVDN0djbzF4eDB4bG1VMkh1SUtDUGlHR19SZw?oc=5","date":"2017-01-26","type":"pipeline","source":"Fierce Pharma","summary":"J&J finally grabs Actelion's marketed meds for $30B, with R&D spinoff to come - Fierce Pharma","headline":"J&J finally grabs Actelion's marketed meds for $30B, with R&D spinoff to come","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNNHk0STFtRUFJYURZaTBOYndFYmREV2w3SmxzRzF2NmRoOFczLU9qZVdxS1ZnN0V1Rjcxcnc1SF80WGc0N3BtXzBzcGtsUFo3VHJjeEtuSTdoVHVxMjNrVTFRRFBQZ05aT2ptM2VWMmV0TjBPSHhYUGZ4WWtNRXJ0Y0c5YlM2ekNwVzJZLWltZ1JwbGFPQ3Z0UzJ4MF8zcW4xb2dqM3dwSzRsVm9iMFVqRUNfQU5zZFhBQ0FvUF9iMTBlTFY3ZFpuMC1zLUJLTDNuc0JHaW5B?oc=5","date":"2017-01-26","type":"deal","source":"PR Newswire","summary":"Johnson & Johnson To Acquire Actelion For $30 Billion With Spin-Out Of New R&D Company - PR Newswire","headline":"Johnson & Johnson To Acquire Actelion For $30 Billion With Spin-Out Of New R&D Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPd1Mwc193akV2SjcxODFwNWtiQV9mNmV1UmJSc3lZXzFZUW1zbDY4VlBwdGtvM2FfTm1FX0wyWm01M1llVlhrZVZEbER2ZDB2RFlJM0xBYXE3ZHlON2h6Z19aczRuQXlETjg1aFN4d2xPSDVnQ1VBR0Z5V2N5aWhjSEh4Z2EzN3ZxdGlGY2h1SQ?oc=5","date":"2016-12-13","type":"deal","source":"WSJ","summary":"Sanofi Is in Talks for Deal With Actelion Pharmaceuticals - WSJ","headline":"Sanofi Is in Talks for Deal With Actelion Pharmaceuticals","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"phase_2":1,"phase_3":9,"marketed":3,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}